Guangzhou Wondfo Biotech Co., Ltd. Class A

Guangzhou Wondfo Biotech Co., Ltd. Class A

SSZSE:300482
15.28
CNY
-0.33
(-2.11%)
-0.12EPS
7.85BMarket Cap
Apr 01Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.8
1.18
1.18
1.32
2.8
3.79
4.69
6.38
7.58
12.86
6.24
6.6
4.3
4.21
Basic EPS, GAAP
0.19
0.32
0.35
0.35
0.52
0.71
0.88
1.44
1.43
2.71
1.1
1.21
-0.13
-0.13
Free Cash Flow per Basic Share
0.25
0.25
0.28
0.06
0.14
0.27
0.3
1.46
0.47
2.49
-0.23
0.09
0.33
- -
Dividend per Share
- -
0.09
0.15
- -
0.08
0.23
0.18
0.2
0.39
0.32
0.51
0.42
0.41
0.12
Book Value per Share
0.78
1.01
1.7
2.05
2.47
4.34
4.99
6.38
7.54
9.77
10.16
11.54
11.57
11.54
Tangible Book Value per Share
0.74
0.97
1.66
1.98
1.81
3.71
4.31
5.77
6.85
8.94
9.32
10.8
10.75
10.73
Basic Weighted Avg Shares
310
309
362
414
409
435
442
440
444
442
443
464
485
467
Sales/Revenue/Turnover
248
365
429
547
1,145
1,650
2,072
2,811
3,361
5,681
2,765
3,065
2,087
1,966
Operating Margin (%)
17.98
24.61
26.59
24.8
25.07
23.64
26.81
30.58
21.15
24.73
18.44
21.47
-4.69
0.11
Depreciation Expense
14
18
21
28
49
72
106
140
204
270
277
272
263
- -
Net Income, GAAP
59
98
125
145
211
308
387
634
634
1,197
488
562
-63
-63
Effective Tax Rate (%)
15.35
14.14
13.04
16.49
15.61
15.29
15.11
15.61
7.04
12.78
9.86
10.21
- -
- -
Profit Margin (%)
23.83
26.92
29.23
26.49
18.39
18.65
18.7
22.56
18.88
21.07
17.64
18.33
-3.02
-3.2
Working Capital
100
153
483
586
577
1,250
1,297
1,465
1,794
2,209
2,749
2,964
2,262
3,081
LT Debt
- -
- -
- -
- -
114
3
21
505
521
544
581
585
9
6
Total Equity
241
313
701
855
1,190
2,150
2,461
2,994
3,504
4,538
4,615
5,650
5,474
5,467
Return on Invested Capital (%)
14.75
26.7
20.39
16.61
19.76
19.32
18.04
20.24
16.65
25.34
9.39
10.02
- -
- -
Return on Capital (%)
23.82
33.9
23.42
18.37
18.18
15.22
14.78
21.67
17.22
26.23
9.79
10.22
- -
- -
Return on Common Equity (%)
27.83
35.45
24.72
18.79
22.51
20.78
18.64
25.04
20.48
31.1
11.01
11.15
-1.15
-1.15

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
599
606
3
LT Borrowings
- -
- -
- -
LT Finance Leases
8
7
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
468
468
468
Market Capitalization
8,585
7,775
7,846

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,457
3,775
3,567
Cash, Cash Equivalents & STI
1,971
2,098
1,474
Accounts Receivable, Net
771
693
691
Inventories
274
323
321
Total Current Liabilities
1,073
1,139
486
Payables & Accruals
- -
- -
- -
ST Debt
599
606
3
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.56%
13.51%
-3.13%
Free Cash Flow
94.16%
74.55%
264.35%
Net Income, GAAP
13%
-13.32%
-111.22%
Sales/Revenue/Turnover
25.84%
3.24%
-31.91%
Total Cash Common Dividend
91,501.02%
24.73%
0.75%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
861
714
606
883
3,065
2025
800
445
- -
397
2,087
2026
582
457
530
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.49
0.29
0.17
0.27
1.21
2025
0.39
- -
- -
-0.42
-0.13
2026
0.18
0.08
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.02
- -
0.42
2025
- -
- -
- -
-0.01
0.41
2026
- -
- -
0.13
- -
- -

Company Description

CEO
Zhong Xiong Peng
Full Time Employees
2,443
Sector
Health technology
Industry
Biotechnology
Address
No.8 Lizhishan Road Guangzhou GD China 510641
IPO Date
Jun 18, 2015
Business
Guangzhou Wondfo Biotech Co., Ltd. (300482.SZ) develops, manufactures, and sells in vitro diagnostic (IVD) products, specializing in point-of-care testing (POCT) reagents, instruments, and chronic disease management solutions. The company offers rapid test kits for COVID-19, influenza (including Flu Series and H7 avian influenza antigen), drug of abuse, infectious diseases, tumors, fertility, sexually transmitted diseases, and maternal & child health; immunofluorescence analyzers and reagents such as FS-1000, FS-2000, and upgraded models for detecting cardiovascular diseases, inflammation, kidney injury, diabetes, renal functions, coagulation, thyroid hormones, rheumatoid arthritis, and respiratory issues; chemiluminescence platforms including the FC-2100 fully automated analyzer; molecular diagnostic systems for nucleic acid amplification in medium-throughput and POCT applications; blood coagulation, optical coagulation, thrombelastography, blood gas, hemoglobin, and automatic chemiluminescence immunoassay analyzers; fully automated pathology staining systems; and consumer diagnostics like WELLlife COVID-19/Flu A&B home tests, pregnancy tests, blood glucose, and cholesterol monitoring solutions. These products support clinical testing, critical illness diagnosis, primary care, epidemic monitoring, forensic applications, and family health management across segments including immunoassay, molecular diagnostics, electrochemistry, immune colloidal gold, immune-fluorescence, dry biochemistry, and pathology with AI integration. Founded in 1992 and headquartered in Guangzhou Science City, Huangpu District, China, the company employs over 3,000 people and distributes its offerings to approximately 150 countries and regions worldwide, with a focus on developing markets along the Belt and Road Initiative, small and mid-sized medical institutions, third-party labs, and hospital emergency settings. In 2024, Wondfo reported revenue of RMB 3.065 billion, up 10.85% year-over-year, with R&D investment of RMB 438 million (14.3% of revenue); it launched 82 new products (75 reagents and 7 devices), advanced IPD transformation across seven key disease areas (cardiovascular & metabolic, oncology, respiratory, infectious diseases, maternal & child health, drug testing, diabetes), gained FDA approval for its WELLlife home test, achieved recognition as China's leading brand in infectious disease rapid testing and top HIV/STD test brand, partnered with JD Health and others for diagnostic collaborations, progressed regulatory approvals for molecular tests, and announced plans for over $15 million investment in an Ethiopian manufacturing facility for African exports.